

## Adam H. Wierzbowski



Partner  
New York  
Tel: +1 (212) 554-1510  
Fax: +1 (212) 554-1444  
adam@blbglaw.com

Adam has represented investors and other plaintiffs in numerous complex litigations that include securities class actions and derivative suits.

Adam was a senior member of the team that recovered over \$1.06 billion on behalf of investors in *In re Merck Vioxx Securities Litigation*, which arose out of the Defendants' alleged misrepresentations about the cardiovascular safety of Merck's painkiller Vioxx. The case was settled just months before trial and after more than 10 years of litigation. During that time, Plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the second largest recovery ever obtained in the Third Circuit, among the 15 largest recoveries of all time, and the largest securities recovery ever achieved against a pharmaceutical company.

Adam was also a senior member of the team that achieved a total settlement of \$688 million on behalf of investors in *In re Schering-Plough Corp./ENHANCE Securities Litigation* and *In re Merck & Co., Inc. Vytarin/Zetia Securities Litigation*, which related to Schering and Merck's alleged misrepresentations about the multi-billion dollar blockbuster drugs Vytarin and Zetia. The combined \$688 million in settlements is the third largest securities class action settlement in the Third Circuit and among the top 25 securities class action settlements of all time. The cases settled after nearly five years of litigation and less than a month before trial.

More recently, Adam was a senior member of the team that obtained \$480 million for investors in the securities class action against Wells Fargo & Co. related to its fake accounts scandal. The settlement is the fourth largest settlement in the Ninth Circuit.

In the *UnitedHealth Derivative Litigation*, which involved executives' illegal backdating of UnitedHealth stock options, Adam also helped recover in excess of \$920 million from the individual Defendants. He also represented investors in the securities litigation against General Motors and certain of its senior executives stemming from that company's delayed recall of vehicles with defective ignition switches, where the parties recovered \$300 million for investors, in the second largest securities class action recovery in the Sixth Circuit.

Adam also helped obtain significant recoveries on behalf of investors in *Minneapolis Firefighters' Relief Association v. Medtronic, Inc. et al.* (\$85 million recovery); *Bach v. Amedisys, et al.* (\$43.75 million recovery); *In re Facebook, Inc., IPO Securities and Derivative Litigation* (\$35 million recovery); *In re Altisource Portfolio Solutions, S.A. Securities Litigation* (\$32 million recovery) and the *Monster Worldwide Derivative Litigation* (recovery valued at \$32 million). He is currently a member of the teams prosecuting *In re EQT Corporation Securities Litigation*; *Allegheny County Employees' Retirement System, et al. v. Energy Transfer LP, et al.*; *In re Myriad Genetics, Inc. Securities Litigation*; *Stichting Depository APG, et al. v. Synchrony Financial, et al.*; and *In re Celgene Corporation Securities Litigation*.

In 2016, Adam was named to *Benchmark Litigation's* "Under 40 Hot List," in recognition of his achievements as one of the nation's most accomplished legal partners under the age of 40. He is also regularly named as one of Thomson Reuter's *Super Lawyers* and a New York "Rising Star." No more than 2.5% of the lawyers in New York are selected to receive this honor each year. Most recently, he was named a 2020 "500 Leading Plaintiff Financial Lawyer" by *Lawdragon*.

## Education

- George Washington University Law School, J.D., 2003, Notes Editor for *The George Washington International Law Review*; Member of the Moot Court Board
- Dartmouth College, B.A., 2000

## Admissions

- New York
- U.S. Supreme Court
- U.S. Court of Appeals, Second Circuit
- U.S. Court of Appeals, Third Circuit
- U.S. Court of Appeals, Fifth Circuit
- U.S. Court of Appeals, Sixth Circuit
- U.S. Court of Appeals, Seventh Circuit
- U.S. Court of Appeals, Eighth Circuit
- U.S. Court of Appeals, Ninth Circuit
- U.S. District Court, Eastern District of Michigan
- U.S. District Court, Southern District of New York
- U.S. District Court, Eastern District of New York

## News

- April 2013 - *The American Lawyer's* "Big Suits" Features Coverage of \$688 Million Recovery in Merck and Schering-Plough Litigation
- September 09, 2008 - Third Circuit Court of Appeals Reverses Dismissal of the Merck VIOXX Securities Litigation

## Publications

- July 2007 - "The SEC: Friend or Foe?" by Adam Wierzbowski

## Awards

- August 2020 - *Lawdragon* Names BLB&G Partners to The 2020 Edition of the "500 Leading Plaintiff Financial Lawyers" List
- October 15, 2019 - *The New York Law Journal* Profiles Adam Wierzbowski – One of Its 2019 "Rising Stars"
- September 2019 - *Lawdragon* Names 20 BLB&G Attorneys Among its "500 Leading Plaintiff Financial Lawyers" list
- September 2019 - 20 BLB&G Attorneys Named by *Super Lawyers* to its 2019 New York Metro Edition
- August 2019 - *Benchmark* Names Three BLB&G Partners to Its "40 & Under Hot List"
- June 2019 - Adam Wierzbowski Named "Rising Star" by *New York Law Journal*
- October 2018 - 20 BLB&G Attorneys Named by *Super Lawyers* to its 2018 New York Metro Edition
- August 2018 - *Benchmark* Names Three BLB&G Partners to Its "40 & Under Hot List"
- September 20, 2017 - *Super Lawyers* Names 21 BLB&G Attorneys to its 2017 New York Metro Edition
- August 1, 2017 - *Benchmark* Again Names Four BLB&G Partners to Its "Under 40 Hot List"
- October 2016 - *Super Lawyers* Names 20 BLB&G Attorneys to its 2016 New York Metro Edition
- August 15, 2016 - Four BLB&G Partners Named to *Benchmark* "Under 40 Hot List"
- September 16, 2015 - 19 BLB&G Attorneys Selected to 2015 *Super Lawyers* New York Metro Edition
- October 28, 2014 - 13 BLB&G Attorneys Selected to 2014 *Super Lawyers* New York Metro Edition

## Cases

- Alere Inc.
- Amedisys, Inc.
- Celgene Corporation
- EQT Corporation
- Energy Transfer LP
- Facebook, Inc. (IPO)
- General Motors Company
- Medtronic, Inc.
- Merck & Co., Inc. (Vioxx-Related)
- Merck & Co., Inc. (Vytorin-Related)
- Meredith Corporation
- Monster Worldwide, Inc.
- Myriad Genetics, Inc.
- Ryder System, Inc.
- Schering-Plough Corporation
- Stericycle, Inc.
- Synchrony Financial
- UnitedHealth Group, Inc.
- Wells Fargo & Company